Western Europe Source: Globocan 2020

Western Europe Source: Globocan 2020

Western Europe Source: Globocan 2020 Number of new cases in 2020, both sexes, all ages Geography Prostate 170 032 (11.9%) Breast 169 016 (11.9%) Other cancers Lung 729 099 (51.2%) 146 460 (10.3%) Colorectum 141 644 (9.9%) Bladder 68 143 (4.8%) Total: 1 424 394 Number of new cases in 2020, males, all ages Numbers at a glance Total population Prostate 170 032 (21.8%) 196146321 Other cancers 357 428 (45.8%) Number of new cases Lung 89 646 (11.5%) Colorectum 77 052 (9.9%) 1424394 Number of deaths Melanoma of skin Bladder 34 745 (4.5%) 51 854 (6.6%) Total: 780 757 559671 Number of new cases in 2020, females, all ages Number of prevalent cases (5-year) Breast 169 016 (26.3%) 4825206 Other cancers Data source and methods 293 891 (45.7%) Colorectum 64 592 (10%) Incidence Lung Population weighted average of the rates of the region- 56 814 (8.8%) specific countries included in GLOBOCAN 2020. Mortality Corpus uteri Melanoma of skin 28 901 (4.5%) 30 423 (4.7%) Population weighted average of the rates of the region- specific countries included in GLOBOCAN 2020. Total: 643 637 Prevalence Summary statistic 2020 Sum of region-specific prevalent cases. Males Females Both sexes Populations included Population 96 374 578 99 771 743 196 146 321 Number of new cancer cases 780 757 643 637 1 424 394 Austria, Belgium, France, Germany, Liechtenstein*, Age-standardized incidence rate (World) 365.3 294.3 325.0 Luxembourg, Monaco*, Switzerland, The Netherlands Risk of developing cancer before the age of 75 years (%) 34.9 27.9 31.2 Number of cancer deaths 310 542 249 129 559 671 Age-standardized mortality rate (World) 127.1 83.9 103.3 Risk of dying from cancer before the age of 75 years (%) 13.0 8.8 10.8 5-year prevalent cases 2 566 404 2 258 802 4 825 206 Top 5 most frequent cancers excluding non-melanoma skin cancer Prostate Breast Prostate (ranked by cases) Lung Colorectum Breast Colorectum Lung Lung Bladder Melanoma Colorectum Melanoma Corpus uteri Bladder * Country not available in GLOBOCAN 2020 but included in the region The Global Cancer Observatory - All Rights Reserved - March, 2021. Page 1 Western Europe Source: Globocan Incidence, Mortality and Prevalence by cancer site New cases Deaths 5-year prevalence (all ages) Cancer Number Rank (%) Cum.risk Number Rank (%) Cum.risk Number Prop. (per 100 000) Prostate 170 032 1 11.9 9.98 31 968 5 5.7 0.76 696 790 723.00 Breast 169 016 2 11.9 9.69 43 706 2 7.8 1.65 711 748 713.38 Lung 146 460 3 10.3 4.07 113 524 1 20.3 2.91 187 685 95.69 Colon 89 741 4 6.3 1.95 42 637 4 7.6 0.69 269 013 137.15 Bladder 68 143 5 4.8 1.53 20 866 7 3.7 0.29 228 288 116.39 Melanoma of skin 65 168 6 4.6 1.99 7 415 17 1.3 0.16 230 212 117.37 Rectum 46 243 7 3.2 1.18 18 235 9 3.3 0.34 150 953 76.96 Pancreas 45 461 8 3.2 0.99 43 336 3 7.7 0.89 33 127 16.89 Non-Hodgkin lymphoma 43 131 9 3.0 1.12 17 423 11 3.1 0.29 138 621 70.67 Kidney 39 869 10 2.8 1.11 16 120 12 2.9 0.30 121 884 62.14 Leukaemia 32 865 11 2.3 0.82 20 683 8 3.7 0.34 97 711 49.82 Corpus uteri 28 901 12 2.0 1.61 6 552 18 1.2 0.23 115 051 115.31 Stomach 28 490 13 2.0 0.66 17 755 10 3.2 0.35 46 865 23.89 Liver 26 128 14 1.8 0.67 23 657 6 4.2 0.54 25 708 13.11 Thyroid 25 089 15 1.8 0.91 1 854 26 0.33 0.03 97 836 49.88 Brain, central nervous system 18 577 16 1.3 0.58 14 557 14 2.6 0.43 56 632 28.87 Oesophagus 18 283 17 1.3 0.52 14 842 13 2.7 0.37 22 854 11.65 Multiple myeloma 18 114 18 1.3 0.43 11 063 16 2.0 0.19 49 957 25.47 Lip, oral cavity 17 770 19 1.2 0.55 5 133 19 0.92 0.14 56 793 28.95 Ovary 15 927 20 1.1 0.81 11 943 15 2.1 0.50 45 757 45.86 Cervix uteri 10 102 21 0.71 0.67 4 296 20 0.77 0.22 31 886 31.96 Oropharynx 10 005 22 0.70 0.35 4 030 21 0.72 0.12 30 983 15.80 Testis 9 307 23 0.65 0.74 349 34 0.06 0.02 43 465 45.10 Larynx 8 632 24 0.61 0.27 3 342 23 0.60 0.09 30 002 15.30 Vulva 6 219 25 0.44 0.26 1 854 25 0.33 0.05 20 610 20.66 Hypopharynx 5 912 26 0.42 0.20 2 402 24 0.43 0.07 11 754 5.99 Anus 5 660 27 0.40 0.17 1 394 28 0.25 0.03 18 569 9.47 Hodgkin lymphoma 5 590 28 0.39 0.20 745 30 0.13 0.02 22 495 11.47 Mesothelioma 4 628 29 0.32 0.09 3 970 22 0.71 0.07 5 237 2.67 Salivary glands 2 750 30 0.19 0.07 1 003 29 0.18 0.02 9 475 4.83 Gallbladder 2 655 31 0.19 0.05 1 731 27 0.31 0.03 2 987 1.52 Penis 2 098 32 0.15 0.11 510 31 0.09 0.02 7 353 7.63 Nasopharynx 1 304 33 0.09 0.04 502 32 0.09 0.01 4 542 2.32 Vagina 939 34 0.07 0.04 350 33 0.06 0.01 2 765 2.77 Kaposi sarcoma 605 35 0.04 0.02 43 35 0.01 0.00 2 041 1.04 All cancer sites 1 424 394 - - 31.24 559 671 - - 10.85 4 825 206 2460.0 Age-standardized (World) incidence rates per sex, top 10 cancers Males Females Breast 90.7 Prostate 77.6 Lung 41.7 25.0 Colorectum 34.3 23.9 Melanoma of skin 19.4 18.9 Bladder 21.5 5.8 Non-Hodgkin lymphoma 12.7 7.8 Kidney 12.9 6.3 Thyroid 4.2 13.8 Leukaemia 10.3 6.9 100 80 60 40 20 0 20 40 60 80 100 ASR (World) per 100 000 Age-standardized (World) incidence and mortality rates, top 10 cancers Incidence Mortality Breast 90.7 15.6 Prostate 77.6 9.8 Lung 32.7 23.8 Colorectum 28.7 10.2 Melanoma of skin 18.9 1.5 Bladder 13.0 3.0 Corpus uteri 12.9 2.0 Non-Hodgkin lymphoma 10.2 2.8 Kidney 9.5 2.8 Testis 9.3 0.27 100 80 60 40 20 0 20 40 60 80 100 ASR (World) per 100 000 The Global Cancer Observatory - All Rights Reserved - March, 2021. Page 2.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us